Best Current Therapeutic Updates Podcasts (2025)

1
THE CONSULT: Professor Paul Klenerman talks with Professor Christopher Buckley about his recent papers. 24:33

Play Pause

6h ago24:33

24:33

These recent papers describe work in the field of stromal cell biology. Fibroblasts were long regarded as simple structural cells and often ignored by immunologists. In these studies of human disease Chris Buckley discusses how recent approaches based on transcriptomics have shone new light on these cells and their role in disease. Given their long…

1
PODCAST: AI in Medicine: Promise and Paradox 1:00:03

4d ago1:00:03

1:00:03

Artificial Intelligence is transforming medicine, from diagnostics and drug discovery to personalised treatment and predictive analytics. But alongside its promise come some important challenges: Algorithmic bias, data privacy, accountability and the tension between human judgment and machine intelligence. This webinar brings together medical scien…

1
THE CONSULT: Rilzabrutinib, Rozanolixizumab, and Beyond: ITP Therapeutics Explored. Professor Paul Klenerman talks to Professor Nichola Cooper about one of her recent papers. 24:11

11d ago24:11

24:11

Immune thrombocytopenia (ITP) is a rare autoimmune disease, but also one where a great deal of progress has been made in development of new therapies. Prof Cooper performs clinical trials to understand the impact of new therapies, based upon and also gaining insights into the underlying pathogenesis. The clear readout of platelet count allows for a…

1
THE CONSULT: A precision medicine approach to colorectal cancer prevention using the omega (n)-3 polyunsaturated fatty acid (PUFA) EPA 47:10

11d ago47:10

47:10

Mark Hull talks about the translational research development of the n-3 PUFA EPA as a cancer prevention agent through to phase 2 and 3 clinical trials, touching on design and delivery of trials of ‘nutraceuticals’ like high-dose n-3 PUFAs, and how such an intervention might impact on cancer. Despite proof of concept from a small, randomised trial o…

1
PODCAST: Malaria Vaccines in Africa 55:19

26d ago55:19

55:19

The Association of Physicians of Great Britain and Ireland presents a discussion with key world leading experts in Malaria vaccines from the World Health Organisation and Oxford. Focusing on how vaccines are transforming Malaria prevention globally. Specifically, looking at the development and implementation of malaria vaccines. Speakers: Malaria v…

1
Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 21:21

29d ago21:21

21:21

Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

1
PODCAST: Inflammation Across Tissues 1:01:31

29d ago1:01:31

1:01:31

Immune Mediated Inflammatory Diseases (IMIDs) are a common and growing problem. Traditional models of research and service delivery silo their management within specific specialities and within adult or paediatric settings. Very often patients with disease in one organ have co-morbid involvement in another, suggesting shared pathogenic pathways. Mo…

1
“Bot Therapist” AI in Healthcare: Ethics, Risk, Benefits & Dangers 9:20

2M ago9:20

9:20

Chat Bot Therapist are you ready? Let’s explore potential dangers, risk, benefits, and emerging opportunities. Is the future already here and the inevitable rolling out? Join Clinical Neuropsychotherapist & Media Mental Health Commentator, Bella Rockman & NPR Radios Jennifer Stayton, for this episode of The Jrock Report. SUBSCRIBE, COMMENT, LIKE, S…

1
Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 24:47

2M ago24:47

24:47

Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

1
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 23:19

3M ago23:19

23:19

Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here.

1
Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases 58:18

4M ago58:18

58:18

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. CME information and select publications here.…

1
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 17:44

4M ago17:44

17:44

Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

1
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances 59:02

4M ago59:02

59:02

Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications here.…

1
Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates 1:28:41

5M ago1:28:41

1:28:41

Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information …

1
For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:27:39

5M ago1:27:39

1:27:39

Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.By Dr. Neil Love

1
THE CONSULT: Prof. Paul Klenerman talks to Prof. Sir Munir Pirmohamed about two of his recent papers. 28:40

5M ago28:40

28:40

In this podcast Professor Sir Pirmohamed describes how his work in immunopharmacology has impacted drug therapy in the field of oncology. His work is impacted the lives of thousands of patients receiving potentially toxic therapies and shows the power of genomic medicine in helping make real-world clinical decisions. Professor Paul Klenerman Sidney…

1
EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:57:51

6M ago1:57:51

1:57:51

Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. CME information and select publications here.By Dr. Neil Love

1
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances 58:22

6M ago58:22

58:22

Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here.…

1
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit 50:15

7M ago50:15

50:15

Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  CME information and select publications here.By Dr. Neil Love

1
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit 52:17

7M ago52:17

52:17

Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.  CME information and select publications here.By Dr. Neil Love

1
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:33:02

8M ago1:33:02

1:33:02

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor 57:28

8M ago57:28

57:28

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.By Dr. Neil Love

1
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances 1:00:02

10M ago1:00:02

1:00:02

Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here…

1
Navigating Dating & Relationships During the Holidays 7:22

12M ago7:22

7:22

Tis’ the Season: Navigating the Pressures of Relationships & Holiday Dating This time of the year – in addition to being the holidays – is also known as “cuffing season.” It is a time of the year when single people look to connect in shorter-term relationships to get through the holidays and colder winter months. It unofficially runs from October t…

1
Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer 48:03

12M ago48:03

48:03

Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.By Research To Practice

1
Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer 58:47

12M ago58:47

58:47

Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.By Research To Practice

1
PODCAST: Diabetes - Painful neuropathy, atrial fibrillation and global health research: An update 1:05:28

12M ago1:05:28

1:05:28

The Association of Physicians of Great Britain and Ireland presents a comprehensive exploration of diabetes complications, hosted by Dr Uazman Alam, Reader at the University of Liverpool and Honorary Consultant Physician in Internal Medicine, Diabetes and Endocrinology. Professor Gregory Lip examines the critical relationship between atrial fibrill…

1
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences 1:00:12

1y ago1:00:12

1:00:12

Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.By Research To Practice

1
“Healing Narcissism, Creating A Healthy You & Healthy Relationship Connections” 35:57

1y ago35:57

35:57

“Healing Narcissism, Creating A Healthy You & Healthy Relationship Connections”Our Autumn 🍂 Podcast Series continues with Therapist, Coach &Author, Matthew Phipher.As we continue to focus on intergenerational healing in our practice and psycho, educational outreach work, in the series, we identify what narcissism looks like, how to identify it, how…

1
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung Cancer 1:05:42

1y ago1:05:42

1:05:42

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.By Research To Practice

1
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences 54:40

1y ago54:40

54:40

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.By Research To Practice

1
The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review 42:46

1y ago42:46

42:46

Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.By Research To Practice

1
The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer 1:00:08

1y ago1:00:08

1:00:08

Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.…

1
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR 58:14

1y ago58:14

58:14

Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.…

1
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations 58:19

1y ago58:19

58:19

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.By Research To Practice

1
Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors 59:20

1y ago59:20

59:20

Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.By Research To Practice

1
Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation 2:03:23

1y ago2:03:23

2:03:23

Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates …

1
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer 1:01:24

1+ y ago1:01:24

1:01:24

Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.By Research To Practice

1
Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung Cancer 1:01:43

1+ y ago1:01:43

1:01:43

Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer 1:00:53

1+ y ago1:00:53

1:00:53

Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.By Research To Practice

1
Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation 47:35

1+ y ago47:35

47:35

Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.By Research To Practice

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer 1:00:48

1+ y ago1:00:48

1:00:48

Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.By Research To Practice

1
Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates 1:14:03

1+ y ago1:14:03

1:14:03

Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.By Research To Practice

1
Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer 1:02:58

1+ y ago1:02:58

1:02:58

Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.By Research To Practice

1
Implications of Recent Data Sets for the Current and Future Management of Lung Cancer 1:30:17

2y ago1:30:17

1:30:17

Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer.…

1
Updates in the Treatment of Patients with EGFR Exon 20 Insertion Mutation NSCLC 10:17

2y ago10:17

10:17

This podcast provides an overview of current and emerging data available in the treatment of EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer, including updates from ESMO 2023. Key takeaways:- Review treatment options for EGFR Exon 20 Insertion Mutations in NSCLC - Review updated clinical data from ELCC and ESMO 2023 - Gain an understandi…

1
Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer 1:01:40

2y ago1:01:40

1:01:40

Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.By Research To Practice

1
Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy 2:43:37

2+ y ago2:43:37

2:43:37

Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease.By Research To Practice

1
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting 32:16

2+ y ago32:16

32:16

Featuring a discussion on key presentations on lung cancer from the 2023 ASCO Annual Meeting, with Dr Matthew Gubens, moderated by Dr Neil Love.By Research To Practice

1
Are Etiquette and Thank You Notes Still Even a Thing and Why It Matters? NPR/KUT Radio. 7:06

2+ y ago7:06

7:06

Summer is a busy time for weddings, especially in June. And especially the Austin, Texas area – even in this heat! Weddings have a lot of customs and behavioral expectations attached to them – etiquette if you will. And that got Central Texas Neuropsychotherapist, LPC, Bella J. Rockman thinking about good manners and behavior – in a time when it ca…